Orchestra BioMed Holdings Inc. Ordinary Shares OBIO · Stock Open Orchestra BioMed Holdings Inc. Ordinary Shares in new tab
Orchestra BioMed Holdings Inc. Ordinary Shares Analysis (OBIO)
Is Orchestra BioMed Holdings Inc. Ordinary Shares a good investment? Orchestra BioMed Holdings Inc. Ordinary Shares (OBIO) is currently trading at 6.25 USD. Market analysts have a consensus price target of 12.14 USD. This suggests a potential upside from current levels.
Earnings Schedule: Orchestra BioMed Holdings Inc. Ordinary Shares is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -1.51.
Investor FAQ
Does Orchestra BioMed Holdings Inc. Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Orchestra BioMed Holdings Inc. Ordinary Shares?
Orchestra BioMed Holdings Inc. Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -0.84.
Company Profile
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Community Discussion